# Comparison of Eohilia With Dupixent on Esophagus Diameter in Patients With Eosinophilic Esophagitis.

> **NCT07358234** · EARLY_PHASE1 · ENROLLING_BY_INVITATION · sponsor: **Mayo Clinic** · enrollment: 60 (estimated)

## Conditions studied

- Eosinophilic Esophagitis (EoE)

## Interventions

- **DRUG:** Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]
- **DRUG:** budesonide oral suspension

## Key facts

- **NCT ID:** NCT07358234
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2026-02-04
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-05-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07358234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07358234, "Comparison of Eohilia With Dupixent on Esophagus Diameter in Patients With Eosinophilic Esophagitis.". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT07358234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*